First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)
Published
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--First-Line Treatment With Merck’s KEYTRUDA Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%)
Full Article